I'm Melissa Lee and this is Fast Monday.

Tonight's trader up, Gai Domi, Tim Seymour, Bono, Eison, and Karen Finnerman.

Tonight on Fast, we are tracking the after-hours action and chairs of Gilead, the stock

popping on FDA approval of its coronavirus treatment

Rondesivir.

We'll bring you all the details straight ahead.

Plus, bonds, banks and builders, why a big breakout in yields could lead to a big breakdown

for one key part of the market and later

bald madness today and shares of gap what the retailer said about the future

that sent that stock flying off the rack but we start off with an earnings

alert on Intel the semi-stock dropping in the after hours after reporting results.

Josh Lipton's got all the details. Josh.

So Melissa, I just checked in with CJ Muse over at Evercore.

He covers the name, rates Intel and Neutral.

I wanted his take.

CJ's calling this a disappointing report relative to expectations.

Says the all-important DCG business disappointed, he's referring there to those higher margin server chips.

Revenue came in at 5.9 billion.

Street was looking for close to 6.22 billion.

Within that unit, CJ saying it looks like cloud demand is holding up, but enterprise and government not so much.

Bottom line, CJ arguing investor apathy likely to continue because he's saying there's just too many uncertainties here

how to get the manufacturing strategy together he says and how much of a

...